{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:51:42Z","timestamp":1790254302303,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bone.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T21:46:04Z","timestamp":1510263964000},"page":"93-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-8694","authenticated-orcid":false,"given":"Gill","family":"Holdsworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Greenslade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joby","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Stencel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hishani","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua Zhu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn K.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2017.11.003_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bone.2017.11.003_bb0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2017.11.003_bb0015","doi-asserted-by":"crossref","first-page":"26464","DOI":"10.1074\/jbc.M112.350108","article-title":"Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors","volume":"287","author":"Holdsworth","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2017.11.003_bb0020","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2017.11.003_bb0025","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2017.11.003_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"van Lierop","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0035","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0040","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bone.2017.11.003_bb0045","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2017.11.003_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0055","first-page":"396","article-title":"Romosozumab treatment in postmenopausal osteoporosis","volume":"376","author":"Cosman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2017.11.003_bb0060","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2017.11.003_bb0065","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0070","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2017.11.003_bb0075","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","article-title":"Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody","volume":"155","author":"Li","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2017.11.003_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"Wnt signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2017.11.003_bb0085","doi-asserted-by":"crossref","first-page":"a015081","DOI":"10.1101\/cshperspect.a015081","article-title":"Secreted and transmembrane Wnt inhibitors and activators","volume":"5","author":"Cruciat","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bone.2017.11.003_bb0090","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/jbmr.2482","article-title":"Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats","volume":"30","author":"Nioi","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bone.2014.07.031","article-title":"Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats","volume":"67","author":"Stolina","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0105","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1359\/jbmr.090403","article-title":"Short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis","volume":"24","author":"Eddleston","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1471-2164-8-127","article-title":"Housekeeping and tissue-specific genes in mouse tissues","volume":"8","author":"Kouadjo","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bone.2017.11.003_bb0115","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M807994200","article-title":"Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation","volume":"284","author":"Veverka","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2017.11.003_bb0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","author":"Chouinard","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.bone.2017.11.003_bb0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2017.11.003_bb0135","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","volume":"32","author":"Kim","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0140","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0145","doi-asserted-by":"crossref","first-page":"14004","DOI":"10.1074\/jbc.M114.628818","article-title":"WNT1-induced secreted Protein-1 (WISP1), a novel regulator of bone turnover and Wnt signaling","volume":"290","author":"Maeda","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2017.11.003_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2016.12.003","article-title":"Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats","volume":"97","author":"Ma","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11505","article-title":"Bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2017.11.003_bb0160","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1210\/jc.2013-3278","article-title":"Serum Dickkopf 1 levels in sclerostin deficiency","volume":"99","author":"van Lierop","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2017.11.003_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/boneres.2014.34","article-title":"High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes","volume":"2","author":"Brommage","year":"2014","journal-title":"Bone Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0170","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/ng1614","article-title":"Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation","volume":"37","author":"Li","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2017.11.003_bb0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2016.04.005","article-title":"Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells","volume":"88","author":"Collette","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0180","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1002\/art.23137","article-title":"Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice","volume":"56","author":"Lories","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2017.11.003_bb0185","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1056\/NEJMoa1509342","article-title":"Cortical-bone fragility\u2014insights from sFRP4 deficiency in Pyle's disease","volume":"374","author":"Simsek Kiper","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2017.11.003_bb0190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bone.2014.12.063","article-title":"Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma","volume":"73","author":"Baker","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0195","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bone.2009.02.012","article-title":"Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells","volume":"44","author":"Cho","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.11.003_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-eular.2291","article-title":"OP0251effects of 2years of treatment with romosozumab followed by 1year of denosumab or placebo in postmenopausal women with low bone mineral density","volume":"74","author":"McClung","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2017.11.003_bb0205","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.11.003_bb0210","first-page":"OR08","article-title":"Retreatment with romosozumab after 12 months of placebo demonstrates similar BMD efficacy compared with initial romosozumab treatment","volume":"38","author":"Kendler","year":"2017","journal-title":"Endocr. Rev."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217304192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217304192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T06:11:11Z","timestamp":1539151871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328217304192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":42,"alternative-id":["S8756328217304192"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.11.003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}